Clinical trials: open to volunteers, in Denmark
Melanoma, Non Small Cell Lung Cancer
Dabrafenib and/or Trametinib Rollover Study
This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have…
- Conditions
- Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers
- Trial name
- NCT03340506
- Testing
- dabrafenib, trametinib
- Where
- 38 sites in United States, Argentina and 13 more
- Volunteers
- 100 people
- Sponsor
- Novartis Pharmaceuticals
Spasticity, Muscle
Effect of Treatment Dairy for Spasticity
1. Assessing whether the treatment diary can help optimize the overall treatment of patients. 2. To assess whether the patient finds the treatment diary useful and worth spending time on.
- Trial name
- NCT03384927
- Where
- Denmark
- Volunteers
- 96 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
ARDS, Human
Pulmonary Immune Cell-microbiome Interactions in ARDS
The overall aim is to compare the composition and spatial heterogeneity of the following in critically ill intensive care unit (ICU) patients: i) immune cell populations and their activation patterns, ii) the surrounding…
- Trial name
- ILLUMINA-1 (NCT05795257)
- Testing
- Bronchoalveolar lavage
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Hvidovre University Hospital
Ischemia, Myocardial, Coronary Artery Disease
Comparison of an Ultra-low Strut Thickness Everolimus-eluting Biodegradable Polymer Stent Versus Durable Polymer Everolimus-eluting Stents in Patients Treated With Percutaneous Coronary Intervention
The objective of this randomized study is to compare the safety and efficacy of the ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent to the everolimus-eluting family stents (durable polymer…
- Conditions
- Ischemia, Myocardial, Coronary Artery Disease, Percutaneous Coronary Intervention (PCI)
- Trial name
- SORT OUT XII (NCT06692140)
- Testing
- Ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent(s), PCI with Everolimus-eluting stents (durable polymer everolimus-eluting Xience or Promus stent(s))
- Where
- 3 sites in Denmark
- Volunteers
- 3,150 people
- Sponsor
- Odense University Hospital
Cancer, Type 2 Diabetes
QoLIDia: Quality of Life in Cancer Patients With Diabetes During Immunotherapy
The goal of this observational study is to see how type 2 diabetes affects quality of life in cancer patients receiving immunotherapy.
- Trial name
- QoLIDia (NCT07466212)
- Where
- 4 sites in Denmark
- Volunteers
- 920 people
- Sponsor
- Odense University Hospital
Alpha 1 Antitrypsin Deficiency
A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)
This study is designed to compare two different weekly doses of a medicine called Alpha1-Proteinase Inhibitor given by injection under the skin with the standard doses of the same medicine given through a vein.
- Trial name
- SWIFT-SC (NCT07555483)
- Testing
- Alpha-1 15%, Liquid Alpha1-PI
- Where
- 22 sites in United States, Denmark and 7 more
- Volunteers
- 40 people
- Sponsor
- Grifols Therapeutics LLC
Mesothelioma, Pancreatic Cancer
A 2-part Phase 1/2 Open-label Trial on ODM-212
An open-label, multi-site, multi-cohort phase 1/2 trial to be conducted in 2 parts (dose escalation and dose expansion/optimisation)
- Conditions
- Mesothelioma, Pancreatic Cancer, NSCLC (Advanced Non-small Cell Lung Cancer)
- Trial name
- TEADCO (NCT07563738)
- Testing
- ODM-212, Ipilimumab and nivolumab, Gemcitabine and nab-paclitaxel
- Where
- 23 sites in United States, Denmark and 5 more
- Volunteers
- 229 people
- Sponsor
- Orion Corporation, Orion Pharma
Maxillary Retrognathism, Children
Treatment of Mandibular Overjet in Children With Maxillary Retrognathism
The project involves a 10-year prospective longitudinal cohort multicentre study where orthodontic treatment and treatment effect is followed in children with Cl III due to maxillary retrognathia who undergo standardized…
- Conditions
- Maxillary Retrognathism, Children, Treatment, Class III Malocclusion
- Trial name
- NCT07706400
- Testing
- Interceptive treatment
- Where
- 3 sites in Denmark, Sweden
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Malmö University
Egg Allergy, Egg Hypersensitivity
Oral Immunotherapy for Children With Egg Allergy
This clinical trial aims to investigate if oral immunotherapy can help children with egg allergy tolerate eggs. Children aged 6-18 months can take part in the trial.
- Conditions
- Egg Allergy, Egg Hypersensitivity, Food Allergy in Children, Food Allergies
- Trial name
- NCT07888439
- Testing
- Oral immunotherapy with egg
- Where
- 5 sites in Denmark
- Volunteers
- 76 people
- Sponsor
- Laura Ozer Kettner
Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
This is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) disease-associated…
- Conditions
- Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor
- Trial name
- NCT04924075
- Testing
- Belzutifan
- Where
- 84 sites in United States, Australia and 20 more
- Volunteers
- 355 people
- Sponsor
- Merck Sharp & Dohme LLC
DLBCL, Diffuse Large B-Cell Lymphoma
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of zilovertamab vedotin (ZV) in combination with standard of care options for the…
- Trial name
- NCT05139017
- Testing
- Zilovertamab vedotin, Rituximab, Gemcitabine
- Where
- 135 sites in United States, Argentina and 24 more
- Volunteers
- 290 people
- Sponsor
- Merck Sharp & Dohme LLC
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0
The BIOMEDE 2.0 study is the second stage of the BIOMEDE multi-arm, multistage rolling programme (adaptive platform protocol). It is a multicenter, randomized, open-label, controlled phase-3 trial evaluating efficacy of ONC201 in…
- Conditions
- Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Midline Glioma, H3K27-altered
- Trial name
- BIOMEDE 2 (NCT05476939)
- Testing
- Everolimus, ONC201, Radiotherapy
- Where
- 56 sites in Belgium, Denmark and 6 more
- Volunteers
- 433 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Advanced Solid Tumors, Colorectal Cancer
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
This is a first-in-human, Phase I, open-label, multicenter, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of VVD-133214…
- Trial name
- NCT06004245
- Testing
- VVD-133214, Pembrolizumab, Bevacizumab
- Where
- 55 sites in United States, Australia and 9 more
- Volunteers
- 280 people
- Sponsor
- Vividion Therapeutics, Inc.
Transcatheter Aortic Valve Implantation, Dental
Impact of Preoperative Dental Screening in Reducing Infective Endocarditis Risk in Transcatheter Aortic Valve Implantation Patients
In Odense University Hospital preoperative dental screening (PDS) protocol for patients treated with Transcatheter Aortic Valve Implantation (TAVI) was changed from mandatory to targeted PDS to between June 2023 to october 2023.
- Conditions
- Transcatheter Aortic Valve Implantation, Dental, Endocarditis
- Trial name
- DENTAVI (NCT06330766)
- Testing
- No preoperative dental screening
- Where
- Denmark
- Volunteers
- 1,000 people
- Sponsor
- Odense University Hospital
Prostatic Neoplasms, Castration-Resistant
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
Substudy 01A is part of a larger research study that is testing experimental treatments for metastatic castration-resistant prostate cancer (mCRPC). The larger study is the umbrella study (U01).
- Trial name
- NCT06353386
- Testing
- Opevesostat, Olaparib, Docetaxel
- Where
- 77 sites in United States, Australia and 18 more
- Volunteers
- 220 people
- Sponsor
- Merck Sharp & Dohme LLC
Atrial Fibrillation, Left Atrial Appendage Absent
Can Patients With Atrial Fibrillation Safely Discontinue Anticoagulant Therapy After Cardiac Surgery? (ATLAAC)
Left atrial appendage (LAA) closure has become a frequent addition to oral anticoagulation in patients with atrial fibrillation who undergo cardiac surgery.
- Conditions
- Atrial Fibrillation, Left Atrial Appendage Absent, Anticoagulant Adverse Reaction
- Trial name
- NCT06401616
- Testing
- OAC will be discontinued for the duration of the trial
- Where
- 6 sites in Denmark
- Volunteers
- 1,220 people
- Sponsor
- Odense University Hospital
Intermediate Risk Non-Muscle Invasive Bladder Cancer
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
A phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants with Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC)
- Trial name
- ABLE-32 (NCT06510374)
- Testing
- Nadofaragene Firadenovec
- Where
- 114 sites in United States, Canada and 8 more
- Volunteers
- 454 people
- Sponsor
- Ferring Pharmaceuticals
Untreated Follicular Lymphoma
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
This is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the Surovatamig (AZD0486) plus rituximab combination compared to Investigator's choice of 3…
- Trial name
- NCT06549595
- Testing
- Surovatamig, R-CHOP, R-CVP
- Where
- 244 sites in United States, Australia and 23 more
- Volunteers
- 1,018 people
- Sponsor
- AstraZeneca
Heart Failure
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
Participants include men and women ≥ 40 years of age with T2DM, established CV disease, a history of HTN with an SBP of at least 130 mmHg at screening, who meet the predefined serum potassium level, and with at least one…
- Trial name
- Prevent-HF (NCT06677060)
- Testing
- Baxdrostat and dapagliflozin
- Where
- 977 sites in United States, Argentina and 33 more
- Volunteers
- 11,300 people
- Sponsor
- AstraZeneca
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
The purpose of this study is to obtain safety, efficacy, and pharmacodynamic data on the use of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy who continued on extended use of vutrisiran, or switched from…
- Trial name
- NCT06679946
- Testing
- Vutrisiran
- Where
- 87 sites in United States, Argentina and 15 more
- Volunteers
- 700 people
- Sponsor
- Alnylam Pharmaceuticals